Rubicon Genomics has announced that it has signed a supply agreement with Kreatech Diagnostics for use of Rubicon?s Omniplex-D whole genome amplification technology.
Rubicon Genomics has announced that it has signed a supply agreement with Kreatech Diagnostics for use of Rubicon’s Omniplex-D whole genome amplification technology.
Under the terms of the agreement, Rubicon will provide proprietary reagents which will incorporate elements of its Omniplex amplification technology to Kreatech for use in the manufacture of Kreatech’s Poseidon fluorescence in situ hybridization probes.
James Koziarz, CEO of Rubicon, commented, “Collaborating with a diverse group of industry leaders is a key part of Rubicon's strategy, and we are very pleased to be working with Kreatech, which offers the broadest commercial portfolio of high quality FISH probes available today."
Herman Volkers, CEO of Kreatech, said, “Use of Rubicon's proprietary pre-analytical amplification reagents during the production process contributes to achievement of this superior performance; therefore we are pleased to conclude this renewed supply agreement with Rubicon Genomics.”
For more information please visit ref="http://www.rubicongenomics.com">www.rubicongenomics.com
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.